Document Detail

Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
MedLine Citation:
PMID:  18602515     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to examine outcomes subsequent to implantation of drug-eluting stents (DESs) and bare-metal stents (BMSs) in patients with diabetes. From January 2002 to June 2005, data from all percutaneous coronary interventions performed in Western Denmark were prospectively recorded. A total of 1,423 consecutive diabetic patients treated with stent implantation (2,094 lesions) were followed up for 15 months. Of these, 871 patients (1,180 lesions) were treated with a BMS, and 552 patients (914 lesions) were treated with a DES. Dual antiplatelet therapy was recommended for 12 months in both treatment groups. Data for death and myocardial infarction (MI) were ascertained from national health care databases. Use of DESs was not associated with increased risk of definite stent thrombosis (adjusted relative risk [RR] 0.76, 95% confidence interval [CI] 0.10 to 3.26) or MI (adjusted RR 0.90, 95% CI 0.53 to 1.52). In the DES group compared with the BMS group, adjusted RRs of target-lesion revascularization (adjusted RR 0.48, 95% CI 0.33 to 0.71), total mortality (adjusted RR 0.66, 95% CI 0.44 to 0.99), and cardiac mortality (adjusted RR 0.53, 95% CI 0.31 to 0.90) decreased by 52%, 34%, and 47%, respectively. In conclusion, use of DESs reduced target-lesion revascularization in diabetic patients receiving routine clinical care. This result was obtained without increased risk of death, stent thrombosis, or MI.
Michael Maeng; Lisette O Jensen; Anne Kaltoft; Hans H T Hansen; Morten Bøttcher; Jens F Lassen; Per Thayssen; Lars R Krusell; Klaus Rasmussen; Lars Pedersen; Henrik T Sørensen; Søren P Johnsen; Leif Thuesen
Related Documents :
15632875 - Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneo...
22773515 - Bilateral paramedian thalamic infarction with hypothalamic dysfunction.
9153365 - Effects of mental stress on myocardial ischemia during daily life.
17161045 - Patterns of use and potential impact of early beta-blocker therapy in non-st-elevation ...
15128945 - Translocation and cleavage of myocardial dystrophin as a common pathway to advanced hea...
17515735 - Preclinical testing of the levitronix ultramag pediatric cardiac assist device in a lam...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2008-05-28
Journal Detail:
Title:  The American journal of cardiology     Volume:  102     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-07     Completed Date:  2008-08-29     Revised Date:  2008-11-06    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  165-72     Citation Subset:  AIM; IM    
Department of Cardiology, Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / therapeutic use
Denmark / epidemiology
Diabetes Complications / mortality*
Drug-Eluting Stents / adverse effects*
Middle Aged
Myocardial Infarction / drug therapy,  etiology*,  mortality*
Platelet Aggregation Inhibitors / therapeutic use
Prospective Studies
Risk Factors
Stents / adverse effects*
Thrombosis / etiology*,  mortality*
Ticlopidine / analogs & derivatives,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel
Comment In:
Am J Cardiol. 2008 Oct 15;102(8):1115-6   [PMID:  18929722 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-...
Next Document:  Percutaneous coronary intervention versus coronary artery bypass grafting as primary revascularizati...